Four years stability of type D personality in patients with moderate to severe psoriasis and its implications for psychological impairment^☆,^☆☆

Abstract

Background:

Psoriasis is a systemic auto-inflammatory disease that is related to an increased risk of organic and psychological comorbidities. Type D is a stable personality trait in healthy subjects but there is no data regarding its stability in patients with moderate-severe psoriasis. Objectives: To assess the stability of type D personality in patients with moderate to severe psoriasis as well as assessing the influence of type D personality on anxiety and depression.

Methods:

Prospective cohort study. Forty psoriasis patients with type D personality and sixtysix patients with psoriasis without type D personality were included in the study. Participants completed the DS14 test and HADS at baseline and four years later.

Results:

At baseline, the prevalence of type D personality was 37.7% and at week 208 it was 27.3%. The stability of type D personality was higher in patients with an incomplete education level and in those who were separated/divorced or windowed. During follow-up, 15% of patients developed type D personality. Male sex, having topical treatment, the presence of previous depression, anxiety, and high levels of negative affectivity at baseline increase the risk of developing type D personality.

Study limitations:

Sample size, psoriasis severity restricted to moderate and severe and all patients being under treatment for psoriasis.

Conclusion

The presence of type D personality varies over time in psoriasis patients. Therefore, type D personality is possibly more a state than a trait phenomenon, modified by environmental factors. Type D personality is associated with a higher risk of anxiety.

KEYWORDS
Anxiety; Depression; Psoriasis; Type D personality

Introduction

Negative Affectivity (NA) and Social Inhibition (SI) are the traits that characterize type D’s ‘‘distressed’’ personality. The person is unable to gain adequate social support, in part due to the high negative affectivity they experience.¹

The prevalence of type D personality in healthy subjects in several studies ranges between 20% and 24.1%.²,³ According to recent research, the frequency of type D personality is increased in patients with psoriasis in contrast to the general population, in the range of 25%-38.7%, and in psoriatic patients, there is also a higher prevalence of anxiety and depression.⁴-⁶ The psychological damage that accumulates over the years in a chronic disease such as psoriasis could be related, at least in part, to a higher prevalence of type D personality in patients with psoriasis.⁷

Since these are developmentally dynamic constructs, personality traits are subject to change but also to stability throughout life.⁸ According to Kupper et al. the stability of type D personality over time is determined by genetic and environmental factors.⁹ A study of Loosman et al. maintains that type D personality is variable over time and its stability is related to the stability of anxiety and depressive symptoms.¹⁰ They suggest that type D personality could be more of a state than a characteristic phenomenon.

There is no data on Type D stability in patients with moderate to severe psoriasis who may experience changes in the presence or absence of disease over time. Conden et al. shows that the prevalence of type D personality was 25.1% one month after myocardial infarction and regarding stability, 6.1% of the patients maintained type D personality during hospitalization and one month and twelve months later.¹¹ Martens et al. show that the prevalence of type D personality was 18.3% during hospitalization for myocardial infarction, and 23.2% at eighteen months post-myocardial infarction.¹² However, studies have shown contradictory results; type D characterization changed before and after cardiac surgery in about 60% of patients.¹³ In contrast to acute events such as myocardial infarction or cardiac surgery, psoriasis is a chronic disease and therefore the stability of type D personality could be higher with the consequences that this entails.

The aim of this study is to determine (1) the stability of type D personality over a four-year period in patients with moderate to severe psoriasis; (2) the factors associated with its stability; (3) the association of these personality traits with depression and anxiety (4) and the factors associated with new-onset of type D personality and the influence of type D personality on anxiety and depression.

Methods

Design and study population

Prospective cohort study. The study sample was consecutively recruited among patients with moderate-severe psoriasis who attended their scheduled follow-up visits at the Psoriasis Unit of Hospital Universitario San Cecilio. The Psoriasis unit serves all patients with moderate to severe psoriasis in our dermatology clinic. All participants provided informed consent to participate in the study. The ethics committee of Hospital Universitario San Cecilio approved the study. (REF:1505-N-19).

The authors’ sample in the study is a representative sample of patients with psoriasis that can be found in a dermatology consultation since it has been extracted from the psoriasis unit that attends all patients with moderate to severe psoriasis in the dermatology clinic with a reference population of 450,000 inhabitants.

A questionnaire with DS14 and HADS tests was provided at baseline and at week 208.

Inclusion and exclusion criteria

The inclusion criteria were as follows: diagnosis of moderate-severe cutaneous psoriasis, aged 18 or older and granted informed consent.

The severity of psoriasis was assessed according to the consensus document of the Spanish Academy of dermatology.¹⁴

‘‘Moderate to severe psoriasis is that which requires or has previously required systemic treatment, this includes conventional drugs, biological agents or photochemotherapy. Systemic treatment is indicated in patients with psoriasis in the following situations: (a) disease not controlled with topical treatments; (b) extensive disease (BSA > 5%-10%) (c) PASI > 7-15; (d) rapid worsening; (e) involving visible areas; (f) functional impairment (palmoplantar, nail, genital or scalp involvement); (g) subjective perception of severity (DLQI > 6-10); (h) extensive erythroderma or pustular psoriasis; and (i) disease associated with psoriatic joint disease’’.

Exclusion criteria

Are summarized in the following: refusal to participate in the study, active dermatological diseases other than psoriasis, treatment with psychoactive drugs, intellectual disability, active malignant disease, and alcohol abuse.

Through clinical interviews and physical examinations, all biometric parameters and sociodemographic data were collected. Arterial hypertension, dyslipidemia and diabetes mellitus were three physical comorbidities that were considered for the analysis as long as the patient was receiving active treatment. The severity of psoriasis was assessed by a trained dermatologist by clinical interview, physical examination, review of medical records, calculation of BSA affected by Psoriasis and Severity Index and Psoriasis Area (PASI).¹⁵

Main endpoints of interest and sources of information

The authors’ main variables of interest were the presence of type D personality assessed by the questionnaire DS14, and the presence of anxiety and depression, which was measured by the Hospital Anxiety and Depression Scale (HADS).

The DS14 questionnaire, validated in the Spanish population, is widely used to assess the presence of type D personality.¹ It is made up of 14 items, 7 related to negative affectivity and 7 to social inhibition. Each is scored from 0 to 4; and a score equal to or greater than 10 in both subscales translates into a type D personality. The DS14 has been translated into different languages and has demonstrated high reliability and internal consistency. The Spanish version of DS14 presents adequate psychometric properties with an alpha coefficient of Cronbach values higher than 0.80 on the scale of negative affection and social inhibition.¹⁶ The DS14 test has shown to have adequate psychometric qualities, to be a stable scale over time, and to have a good internal consistency, independent of mood and health status, as recent studies show.¹,¹²,¹⁷

Levels of anxiety and depression were assessed with HADS.¹⁸ The HADS test has also been validated in the Spanish population.¹⁹ It is made up of fourteen items that are divided into two scales of seven items. Each symptom is scored from 0 to 3 on a 4-point Likert scale according to its strength. Scores higher than 7 on the subscales indicate signs of anxiety or depression; when the marks exceed 10 they translate into a clinical problem. The prevalence of anxiety and/or depression is deduced from scores greater than 7.

Data analysis

Descriptive statistics were used to explore the characteristics of the patients. Continuous data were expressed as mean and Standard Deviation (SD). For qualitative variables, absolute and relative frequency distributions were estimated. To compare quantitative data between psoriatic patients with and without type D personality the Mann-Whitney U test was performed. The Chi-Square test or Fisher’s exact test was used for qualitative variables when necessary. Significance was set at p < 0.05. The main outcomes of interest were type D personality and the presence of anxiety and depression. Type D personality was evaluated in a binary way as to present: DS14 score greater than 10 in both subscales; or absent: scores lower than 10. In the same way, HADS is a binary scale with which the prevalence of anxiety and/or depression was considered for scores higher than 7 in each subscale.

Results

Baseline characteristics of the sample

A total of 154 patients with moderate to severe psoriasis were invited to join the study. Twenty-one patients did not meet the inclusion criteria and were excluded. Three questionnaires were excluded because they were incomplete. Therefore, 130 patients joined the study. At week 208, there were 24 (18.5%) non-responders: two patients had died and twenty-two did not want to participate. Forty psoriasis patients with type D personality (tDp) and sixty-six patients with psoriasis without tDp were included for analysis. Table 1 summarizes the baseline characteristics of the population at week 0.

Type D personality stability

The prevalence of tDp for participants was 37.7% (95% CI 29.08%-47.23%) at baseline and 27.3% (95% CI 19.77%-36.52%) at week 208. 47.5% (95% CI 32.9%-62.05%) of patients maintained tDp. The stability of tDp was higher in patients with incomplete education vs. basic-higher education and patients with separated-divorced-widowed marital status vs. single-married (Table 2). Higher PASI at week 208 and higher levels of negative affectivity at week 0, beta 0.14 (0.07), p = 0,04 also correlated with greater stability of tDp. No association was observed with age, sex, time of evolution, BMI, treatment, or the absolute reduction of PASI from week 0.

Incidence of type D personality

Table 3 summarizes the type D personality incidence data throughout the 208 weeks of follow-up. During follow-up, 15.15% (10/66) of patients who did not have tDp at week 0 developed tDp. Male sex, the presence of previous depression, anxiety, and high levels of AN at baseline 0.17 (0.06), p = 0.004 increase the risk of developing tDp. In the present study’s sample, at week 208, eighteen of the seventy-seven patients without type D personality (23.4%) scored higher than 10 on the NA subscale.

Psychological implications of type D personality

The incidence of anxiety in patients with tDp was 33.3% (5/15) vs. 10.87% (5/46) in patients without tDp, p = 0.413. There were no differences regarding depression 9.52% (2/21) vs. 5.66% (3/53), p = 0.55. Absolute frequencies of anxiety and depression were higher in patients with tDp at baseline and week 208. The prevalence of anxiety and depression regarding tDp status is shown in Table 4.

Discussion

This study examines the stability of type D personality in patients with moderate to severe psoriasis over 208 weeks of follow-up and its relationship with the development of anxiety and depression.

Table 1
Baseline characteristics of the population week 0.

	TDp (n = 40)	No tDp (n = 66)	p-values
Age (years)	52.30 ± 1.97	51.46 ± 1.53	0.74
Male:Female ratio	21:19	10:13	0.41
BMI	28.50 ± 0.95	28.6 ± 0.74	0.92
Educational level (%)			0.15
Primary incomplete	7 (17.50)	4 (6.06)
Secondary	21 (52.50)	36 (54.55)
Academic	12 (30)	26 (39.39)
Marital status (%)			0.66
Single	5 (12.50)	12 (18.18)
Married	30 (75)	48 (71.21)
Others	5 (12.50)	6 (10.61)
Arthropathy (%)			0.69
Yes	13 (32.50)	19 (28.79)
Years of evolution	22.20 ± 1.93	24.14 ± 1.44	0.41
Psoriasis treatment (%)			0.68
Topical	7 (17.50)	9 (13.64)
Classical systemic drugs	14 (35.00)	20 (30.30)
Biological drugs	19 (47.50)	37 (56.06)
Baseline PASI	4.48 ± 0.79	4.14 ± 0.62	0.74
Baseline HADS-A >8	25 (62.5)	20 (30.30)	0.001
Baseline HADS-D >8	19 (47.50)	13 (19.70)	0.002

• TDp, type D personality consists of a tendency to inhibit the expression of emotions or behavior to avoid negative reactions from others (Social Inhibition: SI), in combination with the stable tendency to experience Negative Affectivity (NA).
• Data are expressed as mean ± standard deviation and as number (percentage); BMI, Body Mass Index; PASI, Psoriasis Area and Severity Index; HADS, the Hospital Anxiety and Depression Scale-Anxiety (HADS-A) and -Depression (HADS-D); p-values refer to the comparison of the patient with or without type D personality.

Table 2
Type D personality stability at 208 weeks of follow-up.

	tDp Stable (n = 19)	tDp Loss (n = 21)	p-value
Age (years)	52.78 ± 2.5	51.8 ± 2.38	0.78
Male: female ratio	9:10	12:9	0.53
BMI	28.22 ± 1.62	28.75 ± 1.54	0.81
Educational level primary incomplete vs. secondary-academic	6 (31.58) vs. 13 (68.42)	1 (4.76) vs. 20 (95.24)	0.03
Marital status single-married vs. divorced-windowed	14 (73.68) vs. 5 (26.32)	21 (100.00) vs. 0 (0.00)	0.02
PASI (baseline)	5.14 ± 1.08	3.88 ± 1.02	0.40
PASI (week 208)	3.67 ± 0.79	1.47 ± 0.76	0.05
HADS-A >8 (%)	13 (68.42)	12 (57.14)	0.46
HADS-D >8 (%)	11 (57.89)	8 (38.10)	0.20
Baseline psoriasis treatment (%)			0.29
Topical	3 (15.79)	4 (19.05)
Classical systemic drugs	9 (47.37)	5 (23.81)
Biological drugs	7 (36.84)	12 (57.14)
Final psoriasis treatment (%)			0.39
Topical	1 (5.26)	4 (19.05)
Classical systemic drugs	2 (10.53)	2 (9.52)
Biological drugs	16 (84.21)	15 (71.43)

• TDp, type D personality consists of a tendency to inhibit the expression of emotions or behavior to avoid negative reactions from others (social inhibition: SI), in combination with the stable tendency to experience negative affectivity (NA). Data are expressed as mean ± standard deviation and as number (percentage); BMI, Body Mass Index; PASI, Psoriasis Area and Severity Index; HADS, the Hospital Anxiety and Depression Scale-Anxiety (HADS-A) and Depression (HADS-D); p-values refer to the comparison of patients in whom type D personality remains stable and in those who lose it.

Table 3
Type D personality incidence data throughout the 208 weeks of follow-up.

	Generate tDp (n = 10)	No tDp (n = 56)	p-values
Age (years)	51.20 ± 4.2	51.51 ± 1.8	0.95
Male:Female ratio	1:4	19:9	0.004
BMI	27.63 ± 1.69	28.79 ± 0.71	0.51
Educational level (%)			0.37
Primary incomplete	1 (10.0)	3 (5.36)
Secondary	7 (70.0)	29 (51.79)
Academic	2 (20.0)	24 (42.86)
Marital status (%)			0.97
Single	2 (20.0)	10 (17.86)
Married	7 (70.0)	41 (73.21)
Divorced	1 (10.0)	5 (8.93)
PASI (baseline)	4.04 ± 1.68	4.16 ± 0.71	0.94
PASI (week 208)	1.00 ± 0.72	1.63 ± 0.30	0.42
Baseline HADS-A >8	6 (60.0)	14 (25.0)	0.03
Baseline HADS-D >8	5 (50)	8 (14.29)	0.01
Baseline psoriasis treatment (%)			0.92
Topical	1 (10.0)	8 (14.29)
Classical systemic drugs	3 (30.0)	17 (30.36)
Biological drugs	6 (60.0)	31 (55.36)
Final psoriasis treatment (%)			0.14
Topical	3 (30.0)	5 (9.09)
Classical systemic drugs	0 (0.0)	4 (7.27)
Biological drugs	7 (70.0)	46 (83.64)

• TDp, type D personality consists of a tendency to inhibit the expression of emotions or behavior to avoid negative reactions from others (Social Inhibition: SI), in combination with the stable tendency to experience Negative Affectivity (NA). Data are expressed as mean ± standard deviation and as number (percentage); BMI, Body Mass Index; PASI, Psoriasis Area and Severity Index; HADS, the Hospital Anxiety and Depression Scale-Anxiety (HADS-A) and Depression (HADS-D); p-values refer to the comparison of patients who develop type D and those who do not.

Table 4
Anxiety and depression prevalence at week 0 and 208.

	Week 0		p-values	Week 208		p-values
	tDp (n = 40)	No tDp (n = 66)		TDp (n = 29)	No tDp (n = 77)
HADS-A >8	25 (62.50)	20 (30.30)	0.001	16 (55.17)	19 (24.68)	0.035
HADS-D >8	19 (47.50)	13 (19.70)	0.002	9 (31.03)	7 (9.10)	0.076

• TDp, type D personality consists of a tendency to inhibit the expression of emotions or behavior to avoid negative reactions from others (Social Inhibition: SI), in combination with the stable tendency to experience Negative Affectivity (NA).
• Data are expressed as number (percentage); HADS, the Hospital Anxiety and Depression Scale-Anxiety (HADS-A) and Depression (HADS-D); p-values refer to the comparison of the patient with or without type D personality.

Several studies have shown the stability of type D personality over time. Zoha et al. found temporal stability for the prevalence of Type D in healthy Israeli adults, the prevalence at baseline was 25.3%, which was not statistically different from the prevalence six years later.²⁰ A study by Jellesma et al. shows that the prevalence of type D personality remained stable in Dutch schoolchildren over a period of eighteen months.²¹ Ossola et al. similarly showed that the prevalence of type D was stable over twelve months in Italian intensive care coronary patients.²²

Lim et al. found that in Korean patients the prevalence of type D personality was similar in patients with Cardiovascular Disease (CVD) with respect to patients with arterial hypertension and without CVD and with respect to controls.²³,²⁴ In accordance with the above, the present study shows stability of type D personality of 47.5% over the four years of follow-up.

The characteristics of a personality are dynamic traits that throughout life can experience periods of change and stability.⁸ The authors still do not know the reason why patients with Type D personality are more vulnerable, but this could be related not only to biological but also behavioral factors. Bratko and Butkovic showed that genetic factors were primarily responsible for the four-year stability of Eysenck’s personality traits - extraversion, neuroticism, and psychoticism - in the transition period from adolescence to young adulthood.²⁵ While the changes in personality traits during that period were determined by environmental factors. The stability of the Type D personality, therefore, seems to be due in large part to genetic factors, these factors can contribute to the change of a trait, as well as its continuity.⁹ There are also some environmental factors involved: it seems logical that incomplete education makes the individual understand the disease less which favors the persistence of type D personality. In the same way, it can be affected by vital factors such as having lost a partner.

Within the type D personality, the trait most associated with its stability is having high levels of NA. High-NA makes the person experience more feelings of anxiety, dysphoria, and irritability, generates a negative perspective of himself and reality, thus perceiving imminent problems that are not yet real. In the present study’s sample, 23.4% of patients who did not meet type D personality criteria scored higher than 10 on the NA subscale.

Recent research has shown an increased prevalence of type D personality in patients with psoriasis compared to healthy populations.⁴-⁶ In our study, the prevalence of type D personality is high, (27.3%-37.7%) especially considering they are under treatment as patients of a psoriasis unit. The prevalence is also comparable to the cardiac population (13.5%-35%).²⁶

Personality consists of a set of traits that reflect consistencies over time in the general affective level and the behavior of individuals.²⁷ In the study by Mols et al. it was seen that anxiety levels were higher in cancer patients and type D personality compared to non-type D.²⁸ This is consistent with the literature in patients with and without CVD and in the general population. Type D personality and mood are consistently related, favoring higher levels of anxiety and depression in these patients. Type D personality is consistently related to mood, favoring the presence of anxiety and depression.¹²,²⁹,³⁰ As the authors already know, the interrelation of anxiety, stress and cortisol through the hypothalamic-pituitary-adrenal axis are factors that aggravate psoriasis. Subjects with type D personality and in particular its negative affection subcomponent are more likely to experience negative emotions, depression, anxiety, hostility, irritability, lower levels of self-confidence, and more use of resignation or withdrawal coping strategies.² In the present study’s sample, the incidence of anxiety is three times higher in patients with type D personality throughout the follow-up. Moreover, 23.4% of patients who did not meet type D personality criteria scored higher than 10 in the NA subscale.

Type D personality represents a risk factor for poor prognosis and death in cardiac patients.¹,¹¹ Its prevalence in patients with CVD ranges between 13.5% and 35%.²⁹ This vulnerability, although it remains unknown, could be explained due to genetic and behavioral factors.³¹

There is no previous data on the incidence of type D personality in chronic diseases such as psoriasis, where patients may experience changes in the presence or absence of disease over time and only in acute processes.¹¹,¹²,²⁹ The authors consider that an incidence of 15% is high, considering they are patients under treatment in the psoriasis unit. It seems that the most vulnerable subjects for type D personality are male sex, being under-treated, alterations in mood in the form of anxiety and depression, and again it seems that negative affectivity increases the risk of tDp.

Type D personality is a marker of consistent psychological comorbidity over time and therefore patients with psoriasis and type D personality could be candidates for multidisciplinary team care including psychological care and cognitive behavioral therapy. The authors could consider cognitive-behavioral treatment as a promising framework for intervention. According to previous studies, this could reduce the perceived stigmatization in diseases that affect the skin and thus improve both the psychological results and those related to the disease in patients with psoriasis, it would also help to work the feeling of helplessness in these patients, all of this is significantly correlated with the impact of the disease.³²-³⁴ It is necessary to periodically reassess the presence of type D personality in patients with moderate-severe psoriasis, as new cases may develop over time.

The results of this study should be viewed with caution given some methodological limitations: (1) Limited sample size, (2) Psoriasis severity was limited to moderate to severe, and (3) Patients were under treatment for psoriasis.

Conclusion

In conclusion, the current study provides further evidence for type-D personality being conceptualized as a stable personality construct instead of a trait phenomenon. Type D personality could represent a frequent personality profile in patients with psoriasis which could identify subjects who are more vulnerable to psychological comorbidity and could benefit from a cognitive-behavioral treatment. It is necessary to periodically reassess the presence of type D personality in patients with moderate-severe psoriasis, as new cases may develop over time.

• Financial support
  None declared.

References

• ¹
  Denollet J. DS14: Standard assessment of negative affectivity, social inhibition, and type D personality. Psychosom Med. 2005;67:89-97.
• ²
  Borkoles E, Kaiseler M, Evans A, Ski CF, Thompson DR, Polman RCJ. Type D personality, stress, coping and performance on a novel sport task. PLoS One. 2018;13:1-15.
• ³
  Zohar AH, Denollet J, Ari LL, Cloninger CR. The Psychometric Properties of the DS14 in Hebrew and the Prevalence of Type D Personality in Israeli Adults. Eur J Psychol Assess. 2011;27:274-81.
• ⁴
  van Beugen S, van Middendorp H, Ferwerda M, Smit JV, Zeeuwen-Franssen MEJ, Kroft EBM, et al. Predictors of perceived stigmatization in patients with psoriasis. Br J Dermatol. 2017;176:687-94.
• ⁵
  Basin´ska MA, Wo´zniewicz A. The relation between type D personality and the clinical condition of patients suffering from psoriasis. Postepy Dermatol Alergol. 2013;30:381-7.
• ⁶
  Molina-Leyva A, Caparros-Delmoral I, Ruiz-Carrascosa JC, Naranjo-Sintes R, Jimenez-Moleon JJ. Elevated prevalence of Type D (distressed) personality in moderate to severe psoriasis is associated with mood status and quality of life impairment: A comparative pilot study. J Eur Acad Dermatology Venereol. 2015;29:1710-7.
• ⁷
  Kimball AB, Gieler U, Linder D, Sampogna F, Warren R, Augustin M. Psoriasis: Is the impairment to a patient’s life cumulative? J Eur Acad Dermatology Venereol. 2010;24:989-1004.
• ⁸
  Roberts BW, Caspi A. The cumulative continuity model of personality development: striking a balance between continuity and change in personalitytraits across the life course. In: Staudinger UM, Lindenberger U, editors. Understanding Human Development. Boston: Springer; 2003. p. 183-214.
• ⁹
  Kupper N, Boomsma DI, de Geus EJC, Denollet J, Willemsen G. Nine-year stability of type D personality: Contributions of genes and environment. Psychosom Med. 2011;73:75-82.
• ¹⁰
  Loosman WL, de Jong RW, Haverkamp GLG, van den Beukel TO, Dekker FW, Siegert CEH, et al. The Stability of Type D Personality in Dialysis Patients. Int J Behav Med. 2018;25:85-92.
• ¹¹
  Condén E, Rosenblad A, Ekselius L, Åslund C. Prevalence of Type D personality and factorial and temporal stability of the DS14 after myocardial infarction in a Swedish population. Scand J Psychol. 2014;55:601-10.
• ¹²
  Martens EJ, Kupper N, Pedersen SS, Aquarius AE, Denollet J. Type-D personality is a stable taxonomy in post-MI patients over an 18-month period. J Psychosom Res. 2007;63:545-50.
• ¹³
  Dannemann S, Matschke K, Einsle F, Smucker MR, Zimmermann K, Joraschky P, et al. Is type-D a stable construct? An examination of type-D personality in patients before and after cardiac surgery. J Psychosom Res. 2010;69:101-9.
• ¹⁴
  Llamas-Velasco M, de la Cueva P, Notario J, Martínez-Pilar L, Martorell A, Moreno-Ramírez D. Psoriasis moderada. Propuesta de definición. Actas Dermosifiliogr. 2017;108:911-7.
• ¹⁵
  Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012;66:369-75.
• ¹⁶
  Alcaraz S, Hidalgo MD, Godoy C, Fernández E. Spanish validation of the type d personality scale (DS14). Behav Psychol Psicol Conduct. 2018;26:195-209.
• ¹⁷
  Svansdottir E, Denollet J, Thorsson B, Gudnason T, Halldorsdottir S, Gudnason V, et al. Association of type D personality with unhealthy lifestyle, and estimated risk of coronary events in the general Icelandic population. Eur J Prev Cardiol. 2013;20:322-30.
• ¹⁸
  Stern AF. The Hospital Anxiety and Depression Scale. Occup Med (Lond). 2014;64:393-4.
• ¹⁹
  Navinés R, Castellví P, Moreno-España J, Gimenez D, Udina M, Cañizares S, et al. Depressive and anxiety disorders in chronic hepatitis C patients: Reliability and validity of the Patient Health Questionnaire. J Affect Disord. 2012;138:343-51.
• ²⁰
  Zohar AH. Is type-D personality trait(s) or state? An examination of type-D temporal stability in older Israeli adults in the community. Peer J. 2016;4:e1690.
• ²¹
  Jellesma FC. Health in young people: Social inhibition and negative affect and their relationship with self-reported somatic complaints. J Dev Behav Pediatr. 2008;29:94-100.
• ²²
  Ossola P, De Panfilis C, Tonna M, Ardissino D, Marchesi C. DS14 is more likely to measure depression rather than a personality disposition in patients with acute coronary syndrome. Scand J Psychol. 2015;56:685-92.
• ²³
  Berg M, Svensson M, Brandberg M, Nordlind K. Psoriasis and stress: A prospective study. J Eur Acad Dermatology Venereol. 2008;22:670-4.
• ²⁴
  Lim HE, Lee MS, Ko YH, Park YM, Joe SH, Kim YK, et al. Assessment of the type D personality construct in the Korean population: A validation study of the Korean DS14. J Korean Med Sci. 2011;26:116-23.
• ²⁵
  Bratko D, Butkovic A. Stability of genetic and environmental effects from adolescence to young adulthood: Results of Croatian longitudinal twin study of personality. Twin Res Hum Genet. 2007;10:151-7.
• ²⁶
  Grande G, Romppel M, Barth J. Association between type D personality and prognosis in patients with cardiovascular diseases: A systematic review and meta-analysis. Ann Behav Med. 2012;43:299-310.
• ²⁷
  Watson D, Clark LA, Harkness AR. Structures of personality and their relevance to psychopathology. J Abnorm Psychol. 1994;103:18-31.
• ²⁸
  Mols F, Thong MSY, De Poll-Franse LVV, Roukema JA, Denollet J. Type D (distressed) personality is associated with poor quality of life and mental health among 3080 cancer survivors. J Affect Disord. 2012;136:26-34.
• ²⁹
  Romppel M, Herrmann-Lingen C, Vesper JM, Grande G. Type D personality and persistence of depressive symptoms in a German cohort of cardiac patients. J Affect Disord. 2012;136:1183-7.
• ³⁰
  Hausteiner C, Klupsch D, Emeny R, Baumert J, Ladwig KH. Clustering of negative affectivity and social inhibition in the community: Prevalence of type D personality as a cardiovascular risk marker. Psychosom Med. 2010;72:163-71.
• ³¹
  Pelle AJ, Schiffer AA, Smith OR, Widdershoven JW, Denollet J. Inadequate consultation behavior modulates the relationship between Type D personality and impaired health status in chronic heart failure. Int J Cardiol. 2010;142:65-71.
• ³²
  Papadopoulos L, Bor R, Legg C. Coping with the disfiguring effects of vitiligo: A preliminary investigation into the effects of cognitive-behavioural therapy. Br J Med Psychol. 1999;72:385-96.
• ³³
  Fortune DG, Richards HL, Kirby B, Bowcock S, Griffiths CEM. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol. 2002;146:458-65.
• ³⁴
  Fortune DG, Richards HL, Griffiths CEM, Main CJ. Targeting cognitive-behaviour therapy to patient’s implicit model of psoriasis: Results from a patient preference-controlled trial. Br J Clin Psychol. 2004;43:65-82.

Publication Dates

• Publication in this collection
  18 Oct 2021
• Date of issue
  2021

History

• Received
  12 Dec 2020
• Accepted
  9 Feb 2021
• Published
  15 July 2021